Want to see FLNA full AI Analyst Report?
Top Page
Filana Therapeutics
(NASDAQ:FLNA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.86
▼(-7.85% Downside)
Action:Reiterated
Date:09/25/26
The score is primarily held back by weak financial performance (no revenue, ongoing losses and cash burn, and shrinking equity/assets) and bearish technicals (below major moving averages with negative MACD). Corporate events are mixed—FDA hold lift is supportive, but the Nasdaq bid-price compliance risk is a notable near-term concern—while valuation metrics offer limited help given a negative P/E and no dividend yield data.
Positive Factors
Very low leverage
Near-zero debt reduces mandatory financing costs and limits the risk that creditors constrain strategic decisions. This gives Filana greater flexibility to direct available capital toward clinical development, although the benefit is tempered by its continuing need to fund operations.
Negative Factors
No revenue and recurring losses
The absence of revenue leaves Filana dependent on clinical progress and future commercialization or partnering to create economic value. Persistent losses, including renewed deterioration in 2025, reduce profitability visibility and make the business highly sensitive to development spending and execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Near-zero debt reduces mandatory financing costs and limits the risk that creditors constrain strategic decisions. This gives Filana greater flexibility to direct available capital toward clinical development, although the benefit is tempered by its continuing need to fund operations.
Read all positive factors
Filana Therapeutics (FLNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$39.46M
Dividend Yield207.51%
Average Volume (3M)3.98M
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue GrowthN/A
EPS Growth65.77%
CountryUS
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.66
Shares Outstanding48,307,896
10 Day Avg. Volume1,238,220
30 Day Avg. Volume3,975,023
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.02
Enterprise Value/Market Cap-0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit37.77
Enterprise Value/Ebitda0.79
Forecast
1Y Price Target
$6.50Price Target Upside598.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Filana Therapeutics Business Overview & Revenue Model
Company Description
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational c...
Filana Therapeutics Earnings Call Summary
Earnings Call Date:Nov 07, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of promising progress in clinical trials and financial stability, but also highlighted increased administrative costs and legal challenges. The anticipation of Phase III trial results is a critical point of focus.Positive Updates
Phase III Trial Progress
Announced the last patient visit for the Phase III trial RETHINK-ALZ, with top-line results expected by the end of the year.
Negative Updates
Increased General and Administrative Expenses
G&A expenses increased to $12.9 million from $4.3 million in Q3 2023, mainly due to higher legal expenses and increased compensation costs.
Read all updates
Q3-2024 Updates
Positive
Negative
Phase III Trial Progress
Announced the last patient visit for the Phase III trial RETHINK-ALZ, with top-line results expected by the end of the year.
Read all positive updates
Company Guidance
During Cassava Sciences' Q3 2024 earnings call, CEO Richard Barry provided guidance on the company's upcoming milestones and financial outlook. He emphasized the anticipated release of top-line results from the Phase III RETHINK-ALZ trial before the end of the year, highlighting the potential for a best-in-class treatment for Alzheimer's disease. The company plans to report biomarker data for approximately 100 patients, focusing on plasma markers such as pTau 217, Neurofilament Light Chain (NFL), Glial Fibrillary Acidic Protein (GFAP), and total tau. Financially, Cassava Sciences ended the quarter with $149 million in cash, which is expected to be sufficient for operations through the conclusion of ongoing Phase III trials and into 2026. Net cash used in operations for the first nine months of 2024 was $55.7 million, with projections for the second half ranging between $80 million and $90 million, inclusive of a $40 million SEC settlement. The company's net loss for Q3 was $27.9 million, with R&D expenses decreasing as more patients transition to a lower-cost open-label study.Filana Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -667.00K | -936.00K | 0.00 | -89.42M | -68.03M | 0.00 |
| EBITDA | -31.94M | -90.04M | -141.15M | -104.43M | -78.72M | -32.33M |
| Net Income | -31.95M | -90.97M | -24.34M | -97.22M | -76.25M | -32.38M |
Balance Sheet | ||||||
| Total Assets | 103.90M | 118.36M | 157.53M | 151.66M | 234.83M | 266.78M |
| Cash, Cash Equivalents and Short-Term Investments | 82.68M | 95.50M | 128.57M | 121.14M | 201.01M | 233.44M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 139.00K | 236.00K |
| Total Liabilities | 40.29M | 43.95M | 11.83M | 14.20M | 7.29M | 12.87M |
| Stockholders Equity | 63.61M | 74.40M | 145.70M | 137.47M | 227.54M | 253.91M |
Cash Flow | ||||||
| Free Cash Flow | -20.43M | -32.83M | -117.03M | -82.44M | -80.23M | -52.41M |
| Operating Cash Flow | -19.82M | -32.25M | -116.93M | -82.03M | -77.51M | -30.20M |
| Investing Cash Flow | -602.00K | -581.00K | -103.00K | -414.00K | -2.71M | -22.21M |
| Financing Cash Flow | -345.00K | -239.00K | 124.47M | 2.56M | 47.80M | 192.34M |
Filana Therapeutics Technical Analysis
Negative
0.93
Price Trends
0.88
Negative
1.04
Negative
1.47
Negative
Market Momentum
>-0.01
Negative
47.22
Neutral
25.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FLNA, the sentiment is Negative. The current price of 0.93 is above the 20-day moving average (MA) of 0.82, above the 50-day MA of 0.88, and below the 200-day MA of 1.47, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.22 is Neutral, neither overbought nor oversold. The STOCH value of 25.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FLNA.
Filana Therapeutics Risk Analysis
Filana Therapeutics disclosed 52 risk factors in its most recent earnings report. Filana Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Filana Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $100.82M | -9.39 | -70.44% | ― | ― | 10.04% | |
48 Neutral | $83.39M | -4.56 | -50.17% | ― | ― | 70.27% | |
48 Neutral | $236.58M | -1.69 | -314.08% | ― | 40.21% | 13.40% | |
47 Neutral | $154.40M | -4.12 | -74.36% | ― | 35.89% | 58.70% | |
46 Neutral | $39.46M | -0.94 | -58.78% | 207.51% | ― | 65.77% | |
42 Neutral | $26.94M | -1.14 | -60.32% | ― | ― | 71.26% |
* Healthcare Sector Average
FLNA
Filana Therapeutics
0.82
-3.28
-80.10%
CDXS
Codexis
1.41
-1.09
-43.60%
MCRB
Seres Therapeutics
2.71
-16.52
-85.91%
ANIX
Anixa Biosciences
2.90
-1.62
-35.84%
CGTX
Cognition Therapeutics
0.88
-0.92
-51.33%
CAMP
CAMP4 Therapeutics Corporation
3.77
0.15
4.14%
Filana Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Filana Therapeutics advances simufilam in TSC epilepsy trial
Positive
Sep 22, 2026
On September 22, 2026, Filana Therapeutics announced that the U.S. Food and Drug Administration lifted the full clinical hold on its investigational new drug application for simufilam, clearing the way for a planned Phase 2a proof‑of‑c...
Delistings and Listing ChangesRegulatory Filings and Compliance
Filana Therapeutics Receives Nasdaq Minimum Bid Price Notice
Negative
Sep 18, 2026
On September 17, 2026, Filana Therapeutics, Inc. disclosed that it received a notice from Nasdaq stating that its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, putting the company out of compliance wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.